Portal de Periódicos da CAPES

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

2007; Elsevier BV; Volume: 109; Issue: 12 Linguagem: Inglês

10.1182/blood-2006-05-021071

1528-0020

Chiara Gregorj, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Maria Cristina Scerpa, Fabiana De Cave, Paola Fazi, Marco Vignetti, Antonella Vitale, Marco Mancini, Giuseppe Cimino, Salvatore Palmieri, Francesco Di Raimondo, Giorgina Specchia, Francesco Fabbiano, Nicola Cantore, Federico Mosna, Andrea Camera, Mario Luppi, Luciana Annino, Eustachio Miraglia, Giuseppe Fioritoni, Francesca Ronco, Giovanna Meloni, Franco Mandelli, Michael Andreeff, Michèle Milella, Robin Foà, Agostino Tafuri,

PI3K/AKT/mTOR signaling in cancer

Abstract Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P = .013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P = .027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.